Synlogic, Inc. (NASDAQ:SYBX – Get Free Report)’s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.78 and traded as high as $1.23. Synlogic shares last traded at $1.23, with a volume of 55,117 shares trading hands.
Synlogic Stock Up 2.5%
The company has a fifty day simple moving average of $0.78 and a two-hundred day simple moving average of $0.69. The stock has a market capitalization of $15.07 million, a P/E ratio of -4.73 and a beta of 0.48.
Institutional Trading of Synlogic
Hedge funds and other institutional investors have recently modified their holdings of the company. DRW Securities LLC acquired a new stake in Synlogic in the 4th quarter valued at approximately $27,000. Renaissance Technologies LLC lifted its stake in Synlogic by 116.7% in the fourth quarter. Renaissance Technologies LLC now owns 85,627 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 46,117 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in Synlogic during the third quarter worth about $49,000. Institutional investors and hedge funds own 63.40% of the company’s stock.
About Synlogic
Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
Recommended Stories
- Five stocks we like better than Synlogic
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.
